Clinical Research Of Gefitinib Retreatment For Advanced Non-small Cell Lung Cancer

Objective:To investigate curative effect of gefitinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor on retreatment of advanced non-small cell lung cancer, to explore the influencing factors of curative effect, progression and survival.Methods:Seventy patients withⅢb-Ⅳretreatment non-small cell lung cancer confirmed by pathology or cytology were given orally gefitinib 250mg daily, and were followed up to estimate curative effect, progression free survival, one year survival rate, and its influencing factors.Results:The effective rate was 25%, the control rate was 64.71%, one year survival rate 40%; The patients with female, adenocarcinoma or bronchioloalveolar carcinoma, non-smoking, small focuses, rash, were better on the control rate and progression free survival than with male, SqCa, smoking, big focuses, no-rash(P<0.05). One year survival rate was better in the patients with adenocarcinoma or bronchioloalveolar carcinoma, non-smoking, small focuses, disease control (P<0.05), The Cox multiple regression model showed smoking, size of focus, status of disease control were independent factors of progression of disease, RR(4.989,2.241, 2.900),95%CI(2.150～11.576,1.290～3.892,1.227～6.855).Ⅰ-Ⅱrank rash and diarrhea were most frequent adverse reaction, and did not demand special handling.Conclusion:Gefitinib has good curative effect for the retreatment patients ofⅢb-Ⅳnon-small cell lung cancer, with female, adenocarcinom or bronchioloalveolar carcinoma, non-smoking, small focuses, rash.